September 22, 2017 / 6:37 AM / in a month

BRIEF-Grifols gets FDA approval for Prolastin-C

Sept 22 (Reuters) - GRIFOLS SA:

* SAYS GETS APPROVAL FROM FDA (US FOOD AND DRUG ADMINISTRATION) FOR PROLASTIN-C LIQUID AS A REPLACEMENT THERAPY‍​ TO TREAT RARE GENETIC DISORDER

* SAYS COMMERCIAL LAUNCH OF LIQUID FORMULATION PROLASTIN-C IS SCHEDULED FOR 2018

* THE APPROVAL PROCESS FOR THE PRODUCT ALSO COMMENCED IN EUROPE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below